- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06089668
An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis
A Prospective Observational Study to Evaluate Clinical Characteristics, Current Practice and Outcomes of Adult Patients With Suspected or Confirmed Melioidosis
Study Overview
Detailed Description
This is a prospective observational study to evaluate clinical characteristics, current practice and outcomes of adult patients (age ≥18 years) with suspected or confirmed melioidosis. Determination of microbiologically confirmed acute melioidosis among patients presenting with suspected melioidosis, and determination of clinical outcomes of interest (including all-cause mortality, characterization of organ involvement or organ failure, resolution of sepsis, improvement of renal function, rates of suspected vs. microbiologically confirmed melioidosis, and rates of melioidosis involvement of different organ systems) will be performed. Defining clinical and microbiological outcomes in a standardized manner will enable characterization and selection of the relevant outcome measures to be utilized in future clinical studies of IV epetraborole in acute melioidosis. Patients will be identified through daily, active surveillance of hospital admissions at the investigative sites and review of microbiology laboratory culture results. Data will be extracted from hospital and outpatient medical charts. These data will refine the expected treatment effect of standard-of-care antimicrobial therapy and the consequent statistical power calculations needed for sample size and outcome measure design elements of future clinical trials of IV epetraborole adjunctive therapy in hospitalized patients with suspected acute melioidosis.
Participation in the study requires written informed consent from the patient or from their next-of-kin (if needed) at the time of screening. On day 28 (+7) and day 90 (+7) after enrolment the study team will contact the participant by phone interview with standardized script if the participant is discharged alive prior to the day 28 or day 90. There will be no clinical specimens collected as part of the study protocol, as this study aims to observe clinical characteristics and outcomes among patients with confirmed and suspected acute melioidosis in current clinical practice.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Gabrielle Khedr
- Phone Number: 650-331-9090
- Email: gkhedr@an2therapeutics.com
Study Locations
-
-
-
Vientiane, Lao People's Democratic Republic, Laos
- Recruiting
- Mahosot Hospital
-
-
-
-
-
Khon Kaen, Thailand, 40002
- Recruiting
- Srinagarind Hospital
-
Ubon Ratchathani, Thailand, 34000
- Recruiting
- Sunpasitthiprasong Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males and females 18 years old and greater.
- Thai and Laos nationality (for study site in Thailand and Laos, respectively).
- Required hospitalization
- Community-acquired infection is suspected as the cause of illness (Related terms - e.g. fever, acute fever, community-acquired sepsis, and other infectious diseases [e.g. r/o infectious disease, r/o malaria, r/o dengue, r/o bacteraemia and r/o leptospirosis])
For melioidosis-suspected group ONLY 4a. Community-acquired infection is suspected as the cause of illness (Related terms - e.g. fever, acute fever, community-acquired sepsis, and r/o other infectious diseases [e.g. r/o infectious disease, r/o malaria, r/o dengue, r/o bacteraemia and r/o leptospirosis]) 5a. Hospitalized (at study hospital) for less than 24 hours 6a. Suspected of melioidosis (at least one of the following)
- Ceftazidime or Meropenem has already been prescribed BEFORE screening
- SEPTIC SHOCK (sepsis at screening is defined as SOFA≥2 or qSOFA≥1; and shock at screening is defined as requiring vasopressor to maintain MAP≥65 mmHg)
- SEPSIS (defined as SOFA≥2 or qSOFA≥1) with AN UNDERLYING DISEASE of diabetes, chronic kidney disease, major thalassemia, cancer or on immunosuppressive drug (including steroid)
For melioidosis-confirmed group ONLY 4b. Have any specimen culture or Immunofluorescence Microscopy (IFM) or Polymerase Chain Reaction (PCR) positive for B. pseudomallei 5b. Patient is still in the study hospital (i.e. alive) on the screening day
Exclusion Criteria:
For Melioidosis-suspected Group ONLY
- Have confirmed diagnosis of other infectious diseases (e.g. malaria, dengue, leptospirosis) at screening based on rapid diagnostic tests or confirmatory diagnostic tests
- Non-infectious disease (e.g. stroke, heart attack) is suspected to be a primary cause of the sepsis or shock
- Hospital-acquired infection is suspected by attending physician as the cause of illness
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Data Collection of patients in Thailand with "suspected melioidosis"
Time Frame: 2 years
|
Describe, prospective data collection, the presenting clinical characteristics of patients hospitalized in Thailand with "suspected melioidosis" to understand the presentation of this disease in a contemporaneous, rigorously studied cohort.
|
2 years
|
Data Collection of patients in Thailand with "microbiologically confirmed melioidosis ".
Time Frame: 2 years
|
Describe, prospective data collection, the presenting clinical characteristics of patients hospitalized in Thailand with "microbiologically confirmed melioidosis " to understand the presentation of this disease in a contemporaneous, rigorously studied cohort.
|
2 years
|
Data Collection of patients in Laos with "suspected melioidosis"
Time Frame: 2 years
|
Describe, prospective data collection, the presenting clinical characteristics of patients hospitalized in Laos with "suspected melioidosis" to understand the presentation of this disease in a contemporaneous, rigorously studied cohort.
|
2 years
|
Data Collection of patients in Laos with "microbiologically confirmed melioidosis ".
Time Frame: 2 years
|
Describe, prospective data collection, the presenting clinical characteristics of patients hospitalized in Laos with "microbiologically confirmed melioidosis " to understand the presentation of this disease in a contemporaneous, rigorously studied cohort.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Use ± Immunofluorescence Microscopy (IFM) to Determine the percentage of "suspected melioidosis patients" with microbiologically confirmed disease
Time Frame: 2 Years
|
Use ± IFM to determine the percentage of "suspected melioidosis patients" with microbiologically confirmed disease
|
2 Years
|
Use ± Polymerase Chain Reaction (PCR) to Determine the percentage of "suspected melioidosis patients" with microbiologically confirmed disease
Time Frame: 2 Years
|
Use ± PCR to determine the percentage of "suspected melioidosis patients" with microbiologically confirmed disease
|
2 Years
|
Determine frequency of specific involvement of organ systems involvement in patients with microbiologically confirmed acute melioidosis
Time Frame: 28 days after enrollment
|
Determine the frequency of specific organ system involvement in patients with microbiologically confirmed acute melioidosis
|
28 days after enrollment
|
Measure rate to resolution of bacteremia conversion to negative cultures
Time Frame: 28 days after enrollment
|
Microbiological outcomes in patients with microbiologically confirmed acute melioidosis
|
28 days after enrollment
|
Measure time to resolution of bacteremia conversion to negative cultures
Time Frame: 28 days after enrollment
|
Microbiological outcomes in patients with microbiologically confirmed acute melioidosis
|
28 days after enrollment
|
Frequency of Liver involvement in patients with microbiologically confirmed acute melioidosis (as diagnosed per standard of care)
Time Frame: 28 days after enrollment
|
Frequency of involvement of organ systems in patients with microbiologically confirmed acute melioidosis
|
28 days after enrollment
|
Frequency of Skin involvement in patients with microbiologically confirmed acute melioidosis (as diagnosed per standard of care)
Time Frame: 28 days after enrollment
|
Frequency of involvement of organ systems in patients with microbiologically confirmed acute melioidosis
|
28 days after enrollment
|
Frequency of Lung involvement in patients with microbiologically confirmed acute melioidosis (as diagnosed per standard of care)
Time Frame: 28 days after enrollment
|
Frequency of involvement of organ systems in patients with microbiologically confirmed acute melioidosis
|
28 days after enrollment
|
Frequency of Spleen involvement in patients with microbiologically confirmed acute melioidosis (as diagnosed per standard of care)
Time Frame: 28 days after enrollment
|
Frequency of involvement of organ systems in patients with microbiologically confirmed acute melioidosis
|
28 days after enrollment
|
Time to resolution of sepsis
Time Frame: enrollment through day 90
|
Time in days to resolution of sepsis in patients with microbiologically confirmed acute melioidosis who receive antimicrobial therapy directed against B. pseudomallei
|
enrollment through day 90
|
Time to resolution of fever
Time Frame: enrollment through day 90
|
Time in days to resolution of fever in patients with microbiologically confirmed acute melioidosis who receive antimicrobial therapy directed against B. pseudomallei
|
enrollment through day 90
|
Time to resolution of hypotension
Time Frame: enrollment through day 90
|
Time in days to resolution of hypotension in patients with microbiologically confirmed acute melioidosis who receive antimicrobial therapy directed against B. pseudomallei
|
enrollment through day 90
|
Determine clinical cure rates among patients with of microbiologically confirmed acute melioidosis who are treated with ceftazidime
Time Frame: enrollment through day 90
|
Percentage of each clinical outcome of microbiologically confirmed acute melioidosis by antimicrobial treatment regimen
|
enrollment through day 90
|
Determine clinical cure rates among patients with microbiologically confirmed acute melioidosis who are treated with meropenem
Time Frame: enrollment through day 90
|
Percentage of each clinical outcome of microbiologically confirmed acute melioidosis by antimicrobial treatment regimen
|
enrollment through day 90
|
Determine clinical cure rates among patients with suspected melioidosis who are treated with an appropriate antibiotic in the subset of patients with no other microbiologically confirmed diagnosis
Time Frame: enrollment through day 90
|
Percentage of each clinical outcome of "suspected melioidosis patients" to an appropriate antibiotic (ceftazidime or meropenem) in the subset of patients with no other microbiologically confirmed diagnosis (monomicrobial acute melioidosis)
|
enrollment through day 90
|
Antimicrobial durations of treatment of microbiologically confirmed acute melioidosis
Time Frame: enrollment through day 90
|
Antimicrobial durations of treatment of microbiologically confirmed acute melioidosis (including parenteral therapy during the initial phase of treatment and oral therapy during the eradication phase)
|
enrollment through day 90
|
Determine the rates of Burkholderia pseudomallei eradication in patients with microbiologically confirmed acute melioidosis
Time Frame: 28 days after enrollment
|
Determine microbiological eradication patients with microbiologically confirmed acute melioidosis
|
28 days after enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEL-OB1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melioidosis
-
Myanmar Oxford Clinical Research UnitLao-Oxford-Mahosot Hospital Wellcome Trust Research Unit; Medical Action Myanmar and other collaboratorsCompleted
-
Khon Kaen UniversityCompleted
-
University of OxfordWellcome Trust; Mahidol UniversityUnknown
-
Khon Kaen UniversityUnknownMelioidosis | Head and Neck InfectionThailand
-
Arrevus Inc.Arnasi GroupCompleted
-
Foundation for Innovative New Diagnostics, SwitzerlandCompletedDiagnoses Disease | Acute Febrile Illness | MelioidosisAustralia
-
Institute of Tropical Medicine, BelgiumSRI International; Sihanouk Hospital Center of HOPECompletedSystemic Inflammatory Response Syndrome | Melioidosis | Suspected or Confirmed Bloodstream InfectionsCambodia
-
University Hospital, GenevaUniversity of Khartoum; Institute of Tropical Medicine, Belgium; Institut National... and other collaboratorsCompletedHIV | Tuberculosis | Malaria | Visceral Leishmaniasis | Brucellosis | Relapsing Fever | Leptospirosis | Melioidosis | Human African Trypanosomiasis | Enteric Fever | Rickettsial Diseases | Amoebic Liver AbscessCongo, The Democratic Republic of the, Cambodia, Nepal, Sudan
Clinical Trials on Observational Study
-
Taysha Gene Therapies, Inc.Withdrawn
-
AstraZenecaRecruitingNon-Small Cell Lung CancerUnited States
-
University of ManitobaCompletedObesity | Pregnancy | Cesarean SectionCanada
-
University of Castilla-La ManchaRecruitingKnee OsteoarthritisSpain
-
AstraZenecaRecruiting
-
Drexel UniversityCompletedOsteoporosisUnited States
-
The Aurum Institute NPCKarolinska Institutet; Ludwig-Maximilians - University of Munich; University... and other collaboratorsUnknownRespiratory Tract Infections | Tuberculosis, PulmonaryMozambique, South Africa, Tanzania, Gambia
-
Oslo University HospitalThe Research Council of NorwayRecruitingMesothelioma | Pseudomyxoma Peritonei | Colorectal Carcinoma | Ovarian CarcinomaNorway
-
Oslo University HospitalThe Research Council of NorwayActive, not recruiting
-
AstraZenecaDaiichi Sankyo, Inc.CompletedBreast CancerUnited States, Germany, Italy, Korea, Republic of, United Kingdom, Portugal, Australia, Japan, Canada, France